Latest Options News

Titan Minerals Limited has launched a transaction-specific prospectus offering 4 million new options to its underwriter, exercisable at A$0.70 and expiring in January 2027. The offer, which raises no immediate funds, could inject approximately A$2.8 million upon option exercise.

Empire Energy Group has launched a $28 million equity raise to finance critical development activities in the Beetaloo Basin, targeting first gas sales from its Carpentaria Pilot Project in 2025. The capital raise, combined with a $65 million financing package, underpins the company’s ambition to commercialize one of Australia’s largest low-CO2 shale gas resources.

Challenger Gold has completed a Pre-Feasibility Study for toll milling at its Hualilan Gold Project, revealing strong economics, low capital requirements, and a swift payback period. The study underscores the project's potential to generate significant cash flow over three years through a toll milling arrangement with Austral Gold.

Challenger Gold has raised A$34.5 million through an institutional placement to fund near-term gold production and expand development at its Hualilan project in Argentina.

Focus Minerals has completed the sale of its Laverton Gold Project to Genesis Minerals for A$250 million in cash, marking a significant shift in its asset portfolio. The company now turns its attention to optimising operations at its Coolgardie Gold Project.

Invert Graphite has completed significant acquisitions including South Australian exploration licences and appointed a new CEO and board members, setting the stage for its next growth phase.

QuickFee Limited reports mixed Q4 FY25 results with solid growth in US Pay Now and Australian Finance, offset by a significant US Finance decline due to credit impairment. The company completes a major refinancing and capital raise while maintaining FY25 earnings guidance.

OncoSil Medical has launched a Security Purchase Plan offering discounted shares and free options to eligible shareholders, aiming to accelerate commercialization of its pancreatic cancer treatment device.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

Ovanti Limited is set to raise approximately $1 million through a two-tranche share placement to support its US buy now, pay later expansion and ongoing legal matters.

New Frontier Minerals has secured $1.59 million in funding to launch its inaugural drilling campaign targeting heavy rare earth elements, niobium, and uranium at the Harts Range Project, aligning with favorable US policies on supply chain diversification and nuclear energy.

Star Minerals has completed a $1.6 million placement, welcoming Bain Global Resources as a strategic investor and gearing up for drilling at its Tumblegum South Gold Project.